SCHEDULE: Adage Capital Management Discloses Tango Therapeutics Stake

Adage Capital Management, L.P. has reported beneficial ownership of 12,809,485 shares of Tango Therapeutics, Inc. common stock, representing 8.98% of the class.

Summary

• Adage Capital Management, L.P. (ACM), through its general partner Adage Capital Partners L.P. (ACP), has filed a Schedule 13G, indicating beneficial ownership of Tango Therapeutics, Inc. common stock.
• The filing, amended on May 13, 2026, covers shares held as of March 31, 2026.
• ACM, along with individuals Robert Atchinson and Phillip Gross, collectively hold 12,809,485 shares of Tango Therapeutics' common stock.
• This holding represents 8.98% of the outstanding shares.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It is a routine disclosure of significant shareholding by an investment manager and does not provide new operational or financial information about the company itself.

Positives

• Significant stake of 8.98% held by Adage Capital Management, L.P., suggesting confidence in Tango Therapeutics' long-term prospects.
• The filing indicates that the securities were acquired and are held in the ordinary course of business, implying a standard investment strategy rather than a hostile takeover attempt.

Risks

• The filing does not explicitly detail risks, but any investment in a biotechnology company like Tango Therapeutics inherently carries risks associated with drug development, clinical trials, regulatory approvals, and market competition.

Future Outlook

The filing does not contain forward-looking statements or guidance from Tango Therapeutics, Inc. It solely reports on the beneficial ownership of securities by Adage Capital Management, L.P. and associated individuals.

Management Comments

• "The filing of this statement should not be construed in and of itself as an admission by any Reporting Person as to beneficial ownership of the securities reported herein."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11."

Industry Context

StockSavvy.ai notes that significant institutional ownership, as reported in this Schedule 13G filing by Adage Capital Management, is common in the biotechnology sector. Such filings often signal sustained investor interest and can influence market perception of a company's stability and growth potential.

Stakeholder Impact

• Shareholders: The increased stake by a significant investment manager may be viewed positively, potentially indicating confidence in the company's future, which could support share price stability or growth.
• Management: The filing confirms that the investment is in the ordinary course of business, suggesting no immediate intent to influence control, which allows management to continue with their strategic plans without undue pressure from this specific shareholder.

Key Dates

Keywords

Tango Therapeutics, Schedule 13G, Adage Capital Management, beneficial ownership, common stock, investment, biotechnology, SEC filing